ORIGINAL INVESTIGATION. Vitamin Supplement Use in a Low-Risk Population of US Male Physicians and Subsequent Cardiovascular Mortality
|
|
- Deborah Kory Davidson
- 5 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Vitamin Supplement Use in a Low-Risk Population of US Male Physicians and Subsequent Cardiovascular Mortality Jorg Muntwyler, MD, MPH; Charles H. Hennekens, MD, DrPH; JoAnn E. Manson, MD, DrPH; Julie E. Buring, ScD; J. Michael Gaziano, MD, MPH Background: Although basic research suggests that vitamins may have an important role in the prevention of cardiovascular diseases (CVD), the data from cohort studies and clinical trials are inconclusive. Methods: This prospective cohort study was conducted among male physicians residing in the United States who had no history of CVD or cancer. At baseline, data on use of vitamin E, ascorbic acid (vitamin C), and multivitamin supplements were provided by a self-administered questionnaire. Mortality from CVD and coronary heart disease (CHD) was assessed by death certificate review. Results: Use of supplements was reported by 29% of the participants. During a mean follow-up of 5.5 years, 1037 CVD deaths occurred, including 608 CHD deaths. After adjustment for several cardiovascular risk factors, supplement use was not significantly associated with total CVD or CHD mortality. For vitamin E use, the relative risks (RRs) were 0.92 (95% confidence interval [CI], ) for total CVD mortality and 0.88 (95% CI, ) for CHD mortality; for use of vitamin C, the RRs were 0.88 (95% CI, ) for total CVD mortality and 0.86 (95% CI, ) for CHD mortality; and for use of multivitamin supplements, the RRs were 1.07 (95% CI, ) for total CVD mortality and 1.02 (95% CI, ) for CHD mortality. Conclusions: In this large cohort of apparently healthy US male physicians, self-selected supplementation with vitamin E, vitamin C, or multivitamins was not associated with a significant decrease in total CVD or CHD mortality. Data from ongoing large randomized trials will be necessary to definitely establish small potential benefits of vitamin supplements on subsequent cardiovascular risk. Arch Intern Med. 2002;162: From the Department of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland (Dr Muntwyler); University of Miami School of Medicine, Miami, Fla (Dr Hennekens); and Division of Preventive Medicine (Drs Manson, Buring, and Gaziano) and Cardiovascular Division (Dr Gaziano), Department of Medicine, Brigham and Women s Hospital and Harvard Medical School; Department of Ambulatory Care and Prevention, Harvard Medical School (Dr Buring); Department of Epidemiology, Harvard School of Public Health (Drs Manson and Buring); and the Massachusetts Veterans Epidemiology Research and Information Center, Boston Veterans Affairs Healthcare System (Dr Gaziano), Boston, Mass. OXIDATIVE PROCESSES may play an important role in the pathogenesis of arteriosclerosis. In vitro and in vivo studies suggest that oxidized low-density lipoprotein may promote several steps in atherogenesis, including endothelial cell damage, 1 foam cell accumulation 2-4 and growth, 5,6 and induction of autoantibody formation. 7 Vitamin E and ascorbic acid (vitamin C) might prevent or retard various steps in atherogenesis by inhibiting oxidation of lowdensity lipoprotein 8-10 and other free radical reactions. 11 In many animal models, vitamin E has been shown to prevent early steps of atherogenesis Folic acid and B vitamins are ingredients of most multivitamin formulations. Low plasma levels of these vitamins are associated with increased homocysteine levels. 15 During oxidation of homocysteine, potent reactive oxygen products are formed, including superoxide and hydrogen peroxide. 16 Elevated homocysteine levels are implicated in many untoward effects on vessel walls, including endothelial cell damage 17 and dysfunction, 18 stimulation of smooth muscle cell proliferation, 19 and increased adherence of platelets and coagulation products to the endothelium. 17,20 Human observational studies have raised the possibility of an inverse relationship between vitamin supplementation and the risk of cardiovascular disease (CVD). Vitamin E supplements have been associated with a decrease in risk of CVD events in most, but not all, 24 studies. Vitamin C supplementation has been associated with a reduced risk in few studies, 25 and had no apparent effect in others Although there is evidence that higher serum levels of folic acid and some B vitamins are associated with decreased homocysteine levels, 15 the role of supplementation with multivitamins in prevention of CVD has not been thoroughly studied. Intake of multivitamins was associated with a modest risk reduction in 1 large cohort among women, 26 but another observational study found no association
2 SUBJECTS AND METHODS STUDY POPULATION The Physicians Health Study was a randomized, doubleblind, placebo-controlled trial that tested 2 primaryprevention hypotheses: (1) whether 325 mg of aspirin taken every other day reduces risk of CVD, 35 and (2) whether 50 mg of beta carotene (vitamin A) taken on alternate days decreases the incidence of cancer. 36 Potentially eligible participants in the Physicians Health Study were male physicians aged 40 to 84 years in 1982 who resided in the United States and were without a history of myocardial infarction, stroke, or cancer. Letters of invitation, informed consent forms, and baseline questionnaires were mailed to the physicians who were listed on an American Medical Association mailing tape. By December 31, 1983, physicians had answered the enrollment questionnaire. We excluded participants (16.5%) with a history of CVD (myocardial infarction or angina pectoris, stroke or transient ischemic attack, or use of digitalis, nitrates, or warfarin sodium) and/or cancer except nonmelanoma skin cancer. Participants with no information on vitamin supplementation (n=3490; 3.3%) were also excluded. This left participants for the analyses. DATA COLLECTION On the enrollment questionnaire, respondents reported their age, history of a number of diseases, medications, and risk factors. Study participants also gave information on current use of vitamins E, C, and A and multivitamin supplements. The number of years of vitamin supplementation was reported, as was the brand and the number of vitamin pills taken per week. From this information, we estimated the average daily dose of single vitamins E and C supplements. END POINTS Using the National Death Index, death certificates were obtained for the respondents who died through January 31, The deaths were classified by trained nosologists using the first revision of the Ninth International Classification of Diseases in conjunction with the Automated Classification of Medical Entities Decision Tables to manually select underlying cause of death. End points for this analysis were coronary heart disease (CHD) mortality (codes ) and total CVD mortality (codes ). STATISTICAL ANALYSIS Means or proportions of baseline variables were computed for respondents who used vitamin E, vitamin C, or multivitamin supplements compared with nonusers. Proportional hazard models were used to examine the association of intake of vitamin E, vitamin C, and multivitamin supplements with total CVD mortality and CHD mortality. Because the association of vitamin supplements with CVD mortality was not significantly different among randomized and nonrandomized participants, we combined these groups. We conducted age-adjusted and multivariate-adjusted analyses. Multivariate adjustment included additional control for history of hypertension and history of hypercholesterolemia, diabetes mellitus, smoking, alcohol intake, exercise and body mass index, use of the other vitamin supplements, and randomization status. Secondary models were run to compare the association of vitamin supplements with cardiovascular mortality among subgroups. All relative risks (RRs) are presented with 95% confidence intervals (CIs), and all reported P values are 2-sided. Randomized trial data on the effect of vitamins E and C and multivitamin supplements in prevention of CVDs are limited and inconsistent. There are no completed largescale randomized trials that have tested the benefits or risks of vitamin C or multivitamin supplementation in primary or secondary prevention of CVD. Results from randomized trials of vitamin E supplementation in primary prevention are limited, 28,29 and secondary prevention results are inconsistent To provide further information on the role of antioxidant vitamins, including multivitamins, in prevention of CVDs, we studied this issue in a large cohort of US male physicians. RESULTS Of the participants, (29.0%) were current users of 1 or more supplements of vitamin E, vitamin C, or multivitamins. Among those, 6466 (7.7%) used vitamin E, and (12.6%) used vitamin C supplements. The preparations most often used were multivitamins (20549; 24.6%). Most users of specific vitamin E and C supplements took high daily average doses of these vitamins. For example, 64% of users of vitamin E supplements took 400 IU or more per day from supplements, while only 1.0% reported intake of less than 100 IU per day. Similarly, 73% of users of vitamin C supplements took an average of 500 mg or more per day. A large proportion of participants taking vitamin supplements were long-term users: 49% of vitamin E users, 52% of vitamin C users, and 54% of multivitamin users reported taking supplements for 4 years or longer at baseline. Table 1 summarizes the baseline characteristics of participants taking vitamin E, vitamin C, and multivitamin supplements compared with those who did not report supplement use. Users of vitamin supplements were older than nonusers and more often had a history of hypercholesterolemia. Moreover, users of multivitamins were more likely to be diabetic and/or hypertensive. Participants using vitamin supplements were more likely than nonusers to report exercising regularly and were leaner; users of vitamins E and C were less likely to be current smokers. Self-reported blood pressure and cholesterol levels were similar among users and nonusers of vitamin supplements. During a mean follow-up period of 5.5 years, there were 1037 total CVD deaths and 608 CHD deaths. The RRs of CVD and CHD mortality according to supplement use are summarized in Table 2. Age-adjusted and multivariate-adjusted models were not materially different. Compared with nonusers, among those taking vita- 1473
3 Table 1. Age-Standardized Baseline Characteristics According to Current Intake of Vitamin E, Ascorbic Acid (Vitamin C), or Multivitamin Supplements* Characteristics No Vitamin E Vitamin E No Vitamin C Vitamin C No Multivitamins Multivitamins No. (%) of subjects (92.3) 6466 (7.7) (87.4) (12.6) (75.4) (24.6) Mean ± SD crude age, y 54 ± ± ± ± ± ± 10 Mean age, y Diabetes Hypertension Hypercholesterolemia Smoking status Never Past Current Consumed 1 alcoholic drink per week Exercised once a week Mean body mass index, kg/m Mean blood pressure, mm Hg Systolic Diastolic Mean total cholesterol, mg/dl (mmol/l) 211 (5.46) 209 (5.41) 211 (5.46) 208 (5.39) 211 (5.46) 209 (5.41) *Unless otherwise indicated, data are percentages of subjects. Self-reported. Table 2. Relative Risks (95% Confidence Intervals) of Total Cardiovascular Disease (CVD) and Coronary Heart Disease (CHD) Mortality According to Vitamin Supplementation Vitamin CVD CHD Vitamin E Age adjusted 0.91 ( ) 0.84 ( ) Multivariate adjusted* 0.92 ( ) 0.88 ( ) Ascorbic acid (vitamin C) Age adjusted 0.93 ( ) 0.85 ( ) Multivariate adjusted* 0.88 ( ) 0.86 ( ) Multivitamin Age adjusted 1.08 ( ) 1.02 ( ) Multivariate adjusted* 1.07 ( ) 1.02 ( ) *Adjusted for history of hypertension, history of hypercholesterolemia, current and past smoking, alcohol intake, physical activity, body mass index, complementary vitamins, and randomization status; n= min E supplements the RRs of total CVD mortality (multivariate RR, 0.92; 95% CI, ; P=.52) and CHD mortality (multivariate RR, 0.88; 95% CI, ; P=.47) were nonsignificantly reduced. Similarly, for vitamin C users, there was a tendency toward a decrease in CHD (RR, 0.86; 95% CI, ; P=.34) and CVD mortality (RR, 0.88; 95% CI, ; P=.29). Intake of multivitamins was not associated with an increase or decrease in CHD (RR, 1.02; 95% CI, ; P=.88) or CVD mortality (RR, 1.07; 95% CI, ; P=.46). To test whether the association between vitamin E supplements and CVD mortality was modified by intake of vitamin C supplements, we performed analyses including an interaction term for vitamins E and C. We found no significant effect modification (CHD mortality, P=.45; CVD mortality, P=.45). Compared with those taking neither, those taking both vitamin E and vitamin C supplements had an RR for CHD mortality of 0.69 (95% CI, ) and an RR of 0.76 (95% CI ) for CVD mortality. We performed secondary analyses to explore whether subgroups of this cohort potentially benefited from vitamin supplements (Table 3). Among physicians who took 500 mg of vitamin C or more per day, the risk of CVD mortality tended to be reduced (RR, 0.81; 95% CI, ). Conversely, among those taking high daily doses of vitamin E and at least daily multivitamin supplements, the risk of total CVD mortality was slightly elevated (RR, 1.09; 95% CI, for vitamin E; RR, 1.11; 95% CI, for multivitamins), but these results were far from statistical significance. Long-term intake of vitamin E was associated with a tendency toward reduced risk (RR, 0.82; 95% CI, ), but there was no relationship between duration of supplement intake and cardiovascular risk for vitamin C and multivitamins. Among the subgroup of users of vitamins E and C supplements without major cardiovascular risk factors at baseline, there was an indication toward a decrease in risk of total CVD mortality (RR, 0.72; 95% CI, ) and CHD mortality (RR, 0.68; 95% CI, ). COMMENT In this large prospective cohort study among apparently healthy US male physicians, use of vitamin E, vitamin C, and multivitamin supplements was not significantly associated with a decrease or increase in risk of total CVD mortality or CHD mortality. There were nonsignificant trends toward lower risk associated with use of vitamin C and vitamin E supplementation among those without cardiovascular risk factors. In observational primary prevention studies, vitamin E supplementation has been associated with a reduction in cardiovascular risk of 20% to 40% in most, 21-23,37 but not all, 24 studies. Several randomized trials of vitamin E supplements among high-risk populations have been published. In the Alpha-Tocopherol, Beta Carotene Cancer Prevention Study, 28 in which current smok- 1474
4 Table 3. Subgroup Analysis for Relative Risks Among Participants Taking Vitamin Supplements Vitamin E Supplementation Ascorbic Acid (Vitamin C) Vitamins E and C Multivitamins Total CVD mortality High-dose supplementation 1.09 ( ) 0.81 ( ) 0.91 ( ) 1.11 ( ) Supplement intake for 4 y at baseline 0.82 ( ) 0.87 ( ) 0.88 ( ) 1.02 ( ) Without major CVD risk factors 0.72 ( ) 0.68 ( ) 0.66 ( ) 1.13 ( ) CHD mortality High-dose supplementation 0.80 ( ) 0.81 ( ) 0.84 ( ) 0.97 ( ) Supplement intake for 4 y at baseline 0.41 ( ) 0.91 ( ) 0.75 ( ) 0.91 ( ) Without major CVD risk factors 0.71 ( ) 0.65 ( ) 0.59 ( ) 1.01 ( ) *All data are relative risks (95% confidence intervals) adjusted for history of hypertension, history of hypercholesterolemia, diabetes mellitus, current and past smoking, alcohol intake, body mass index, complementary vitamins, and randomization status. CVD indicates total cardiovascular disease. Models for mean daily vitamin E supplementation of 400 IU or more, vitamin C of 500 mg/d or more, and multivitamins of 1 or more pills per day, respectively. Participants without hypertension, hypercholesterolemia, or diabetes mellitus, and not current smokers. ers including those with a history of myocardial infarction were randomized to vitamin E (50 mg/d) or placebo regimens, CVD mortality was similar between the 2 groups (RR, 0.98 for the vitamin E group compared with placebo). The dose of vitamin E used in this trial was lower than that associated with decreased risk in observational studies, and it has been suggested that this dose might have been too low to exhibit a protective effect. 38 In the Cambridge Heart Antioxidant Study (CHAOS), 30 conducted among patients with established CHD, the primary end point of combined fatal and nonfatal cardiovascular events was significantly reduced among those randomized to vitamin E. While CVD mortality was nonsignificantly increased by 18%, the number of deaths was very small. In the Secondary Prevention with Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE) trial, 33 vitamin E reduced the risk of CVD events. However, in 3 other trials, the Primary Prevention Project (PPP), 29 GISSI-Prevenzione, 31 and the Heart Outcomes Prevention Evaluation (HOPE) study, 32 all conducted among high-risk patients or those with CHD, vitamin E supplementation did not reduce CVD event rates. In the GISSI trial 31 there was a nonsignificant trend toward lower CVD rates among those assigned to vitamin E. The RRs among those randomized to vitamin E were 0.94 for CVD mortality and 0.91 for CHD mortality. In our observational primary prevention study, the RRs for total CVD (0.92) and CHD (0.88) mortality were very close to the latter results. Among participants who took supplements of 400 IU of vitamin E or more per day, there was no evidence for a larger benefit. In subgroups of participants without major cardiovascular risk factors at baseline and among long-term users, intake of vitamin E supplements was compatible with a small benefit, but the CIs were wide. Compared with data on vitamin E use, observational evidence that intake of vitamin C supplements decreases CVD risk is weaker, 21-23,25 and clinical trial results are not yet available. As was the case for vitamin E, in this cohort the RR of CHD mortality among users of vitamin C was slightly lower than among nonusers. Among participants who used higher daily supplement doses and in those without major cardiovascular risk factors at baseline, the apparent risk reduction was more pronounced. These subgroup findings may be due to chance or uncontrolled subgroup confounding, or they may represent a true small benefit of vitamin C supplementation. While most multivitamins contain lower amounts of antioxidants than single-vitamin supplements, they contain other potentially beneficial ingredients. In particular, folic acid and B vitamins may be beneficial by lowering serum homocysteine levels. In a cohort of US nurses, multivitamin use was associated with a small but statistically significant 24% reduction in cardiovascular risk, and a 29% reduction among long-term users, 26 but there was no apparent benefit found in another observational study. 27 In our cohort, we found neither an increase nor a decrease in risk among users of multivitamins. This lack of association was stable across subgroups. Specifically, long-term users of multivitamins had an RR for CVD mortality of Further studies are necessary to determine whether use of multivitamins can decrease cardiovascular risk in adequately nourished populations, or whether population segments with low intake of fruits and vegetables benefit from multivitamin use. Our study has several potential limitations. We were able to adjust our models for traditional cardiovascular risk factors, and the similarity of age-adjusted and multivariate-adjusted models suggests that residual confounding by these known variables is unlikely. However, this does not exclude residual confounding because self-selection for vitamin intake may be associated with uncontrolled or uncontrollable confounders. For example, if a larger proportion of participants with unreported diseases used vitamin supplements than truly healthy participants, the risk estimates would tend to be biased toward no benefit or an increase in risk. Conversely, in observational studies there is a possible bias toward an overestimation of the benefits of vitamin supplementation. In addition to healthier lifestyle practices and a more favorable cardiovascular risk profile among supplement users, other factors might account for a distortion of the risk estimates toward an apparent benefit, including improved access to health care or better knowledge of medical conditions requiring urgent treatment. Because our cohort consists of physicians, these potential sources of confounding should be smaller than in most other observational studies. Another potential limitation of our study is that we had no measurements of adherence to vitamin use dur- 1475
5 ing the follow-up period. It is likely, however, that among long-term users at baseline, supplement intake remained fairly stable during the follow-up period, and in this subgroup the associations were close to those for the whole cohort. Similarly, if many physicians had started using vitamin supplements during the observation period, the result could be biased toward no effect. However, during this period, large cohort studies suggesting a benefit of vitamin supplements had not yet been published, and vitamin supplement intake was stable in the US general population. 39 Misclassification of non-cvds as CVDs on death certificates could potentially attenuate the estimate of a benefit of vitamin supplementation. In the randomized part of the cohort, however, death certificate diagnoses of CVD agreed very well with confirmation from hospital records. As our study included a population of well-nourished men, the results cannot be extended to poorly nourished populations. In conclusion, in this large cohort of apparently healthy US male physicians, there was no clear decrease or increase in mortality from total CVD or CHD among users of vitamin E, vitamin C, and multivitamin supplements. There was a suggestion of benefit among those at low risk. Because our study is observational, these data cannot exclude a benefit of vitamin supplements in the primary prevention of CVDs. Data from ongoing large-scale randomized trials will be necessary to establish small potential effects of vitamin supplements on subsequent cardiovascular risk among those at usual or low risk of CHD. Accepted for publication November 19, This research was supported by investigator-initiated research grant HL from the National Heart, Lung, and Blood Institute, Bethesda, Md. We thank Marty Van Denburgh, BA, for his excellent programming. Corresponding author: J. Michael Gaziano, MD, MPH, Brigham and Women s Hospital, 900 Commonwealth Ave E, Boston, MA ( gaziano@maveric.org). REFERENCES 1. Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis. 1983;3: Schaffner T, Taylor K, Bartucci EJ, et al. Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages. Am J Pathol. 1980; 100: Gerrity RG. The role of the monocyte in atherogenesis, I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103: Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low-density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987;84: Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low-density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979;76: Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low-density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A. 1980; 77: Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339: Reaven PD, Khouw A, Beltz WF, Parthasarathy S, Witztum JL. Effect of dietary antioxidant combinations in humans: protection of LDL by vitamin E but not by beta-carotene. Arterioscler Thromb. 1993;13: Retsky KL, Freeman MW, Frei B. Ascorbic acid oxidation product(s) protect human low-density lipoprotein against atherogenic modification: anti- rather than prooxidant activity of vitamin C in the presence of transition metal ions. J Biol Chem. 1993;268: Mosca L, Rubenfire M, Mandel C, et al. Antioxidant nutrient supplementation reduces the susceptibility of low-density lipoprotein to oxidation in patients with coronary artery disease. J Am Coll Cardiol. 1997;30: Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87: Williams RJ, Motteram JM, Sharp CH, Gallagher PJ. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis. 1992;94: Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J. 1993;125: Parker RA, Sabrah T, Cap M, Gill BT. Relation of vascular oxidative stress, alphatocopherol, and hypercholesterolemia to early atherosclerosis in hamsters. Arterioscler Thromb Vasc Biol. 1995;15: Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270: Welch GN, Upchurch G Jr, Loscalzo J. Hyperhomocyst(e)inemia and atherothrombosis. Ann N Y Acad Sci. 1997;811: Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. N Engl J Med. 1974;291: Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997;95: Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994;91: Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58: Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328: Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328: Losonczy KL, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr. 1996;64: Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996;334: Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 1992;3: Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998; 279: Watkins ML, Erickson JD, Thun MJ, Mulinare J, Heath Jr CW. Multivitamin use and mortality in a large prospective study. Am J Epidemiol. 2000;152: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers: the Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330: Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2000;357: Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347: Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354: Yusuf S, Dagenais G, Pogue J, et al, and the Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med. 2000;342: Boaz M, Smetana S, Weinstein T, et al. Secondary Prevention With Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356: Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349: Steering Committee of the Physicians Health Study Research Group. Final report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med. 1989;321: Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334: Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol. 1994;139: Steinberg D, Lewis A. Conner Memorial Lecture: oxidative modification of LDL and atherogenesis. Circulation. 1997;95: Bender MM, Levy AS, Schucker RE, Yetley EA. Trends in prevalence and magnitude of vitamin and mineral supplement usage and correlation with health status. J Am Diet Assoc. 1992;92:
THERE is growing evidence that the oxidative modification
1156 THE NEW ENGLAND JOURNAL OF MEDICINE May 2, 1996 DIETARY ANTIOXIDANT VITAMINS AND DEATH FROM CORONARY HEART DISEASE IN POSTMENOPAUSAL WOMEN LAWRENCE H. KUSHI, SC.D., AARON R. FOLSOM, M.D., RONALD J.
More informationVitamin E and heart disease: a case study 1,2
Vitamin E and heart disease: a case study 1,2 Lawrence H Kushi ABSTRACT The role of nutritional epidemiology studies in the development of nutritional recommendations has been controversial, in part because
More informationThe New England Journal of Medicine VITAMIN E SUPPLEMENTATION AND CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS
VITAMIN E SUPPLEMENTATION AND CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS* ABSTRACT Background Observational and experimental studies suggest
More informationThe oxidative modification hypothesis of coronary heart
Plasma Carotenoids and Tocopherols and Risk of Myocardial Infarction in a Low-Risk Population of US Male Physicians A. Elisabeth Hak, MD, PhD; Meir J. Stampfer, MD, DrPH; Hannia Campos, PhD; Howard D.
More informationFolate, vitamin B 6, and vitamin B 12 are cofactors in
Research Letters Dietary Folate and Vitamin B 6 and B 12 Intake in Relation to Mortality From Cardiovascular Diseases Japan Collaborative Cohort Study Renzhe Cui, MD; Hiroyasu Iso, MD; Chigusa Date, MD;
More informationORIGINAL INVESTIGATION. Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease
ORIGINAL INVESTIGATION Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease Vicki A. Jackson, MD; Howard D. Sesso, ScD; Julie E. Buring, ScD; J. Michael Gaziano, MD Background:
More informationAlthough the association between blood pressure and
Two-Year Changes in Blood Pressure and Subsequent Risk of Cardiovascular Disease in Men Howard D. Sesso, ScD, MPH; Meir J. Stampfer, MD, DrPH; Bernard Rosner, PhD; J. Michael Gaziano, MD, MPH; Charles
More informationORIGINAL INVESTIGATION. Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study
ORIGINAL INVESTIGATION Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study Nancy R. Cook, ScD; Patricia R. Hebert, PhD; JoAnn E. Manson,
More informationORIGINAL INVESTIGATION. Randomized Trials of Vitamin E in the Treatment and Prevention of Cardiovascular Disease
ORIGINAL INVESTIGATION Randomized s of Vitamin E in the Treatment and Prevention of Cardiovascular Disease Rachel S. Eidelman, MD; Danielle Hollar, PhD; Patricia R. Hebert, PhD; Gervasio A. Lamas, MD;
More informationAbundant evidence has accumulated supporting the association
Folate, Vitamin B 6, and B 12 Intakes in Relation to Risk of Stroke Among Men Ka He, MD; Anwar Merchant, DMD; Eric B. Rimm, ScD; Bernard A. Rosner, PhD; Meir J. Stampfer, MD; Walter C. Willett, MD; Alberto
More informationEpidemiological studies indicate that a parental or family
Maternal and Paternal History of Myocardial Infarction and Risk of Cardiovascular Disease in Men and Women Howard D. Sesso, ScD, MPH; I-Min Lee, MBBS, ScD; J. Michael Gaziano, MD, MPH; Kathryn M. Rexrode,
More informationFruit and vegetable intake and risk of cardiovascular disease: the Women s Health Study 1,2
Fruit and vegetable intake and risk of cardiovascular disease: the Women s Health Study 1,2 Simin Liu, JoAnn E Manson, I-Min Lee, Stephen R Cole, Charles H Hennekens, Walter C Willett, and Julie E Buring
More informationALTHOUGH STROKE-RELATED
ORIGINAL CONTRIBUTION Whole Grain Consumption and Risk of Ischemic Stroke in Women A Prospective Study Simin Liu, MD, ScD JoAnn E. Manson, MD, DrPH Meir J. Stampfer, MD, DrPH Kathryn M. Rexrode, MD Frank
More informationA Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II
A Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II Presenter Disclosure Information Howard D. Sesso, ScD, MPH Relevant Disclosures:
More informationDietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women
07/14/2010 Dietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women First Author: Wang Short Title: Dietary Fatty Acids and Hypertension Risk in Women Lu Wang, MD, PhD, 1 JoAnn E.
More informationThe Impact of Diabetes Mellitus and Prior Myocardial Infarction on Mortality From All Causes and From Coronary Heart Disease in Men
Journal of the American College of Cardiology Vol. 40, No. 5, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02044-2
More informationNutritional Epidemiology
Nutritional Epidemiology Multivitamin Supplements Are Inversely Associated with Risk of Myocardial Infarction in Men and Women Stockholm Heart Epidemiology Program (SHEEP) 1 Christina Holmquist,* Susanna
More informationThe New England Journal of Medicine PRIMARY PREVENTION OF CORONARY HEART DISEASE IN WOMEN THROUGH DIET AND LIFESTYLE. Population
PRIMARY PREVENTION OF CORONARY HEART DISEASE IN WOMEN THROUGH DIET AND LIFESTYLE MEIR J. STAMPFER, M.D., FRANK B. HU, M.D., JOANN E. MANSON, M.D., ERIC B. RIMM, SC.D., AND WALTER C. WILLETT, M.D. ABSTRACT
More informationDiabetes and All-Cause and Coronary Heart Disease Mortality Among US Male Physicians
Universidade de Sao Paulo From the SelectedWorks of Paulo A Lotufo 2001 Diabetes and All-Cause and Coronary Heart Disease Mortality Among US Male Physicians Paulo A Lotufo, Universidade de São Paulo JoAnn
More informationAntioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts 1 3
Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts 1 3 Paul Knekt, John Ritz, Mark A Pereira, Eilis J O Reilly, Katarina Augustsson, Gary E Fraser, Uri Goldbourt, Berit
More informationThe role of antioxidant vitamins in the primary
SPRING 2003 PREVENTIVE CARDIOLOGY 85 Treatment of Atherosclerosis in the New Millennium: Is There a Role for Vitamin E? Emma A. Meagher, MD From the Center for Experimental Therapeutics and Department
More informationAtherosclerotic cardiovascular disease (CVD) involving. Vitamin Supplementation and Cardiovascular Disease CLINICAL REVIEW. William T.
Vitamin Supplementation and Cardiovascular Disease William T. Donahoo, MD Abstract Objective: To review the evidence of the effectiveness of antioxidant vitamins for the prevention and treatment of cardiovascular
More informationIN SEVERAL ARTICLES, NUTRIENTS IN
ORIGINAL CONTRIBUTION Fruit and Vegetable Intake in Relation to Risk of Ischemic Stroke Kaumudi J. Joshipura, ScD Alberto Ascherio, MD JoAnn E. Manson, MD Meir J. Stampfer, MD Eric B. Rimm, ScD Frank E.
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationMeasures of Obesity and Cardiovascular Risk Among Men and Women
Journal of the American College of Cardiology Vol. 52, No. 8, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.03.066
More informationAppendix 1 Characteristics of Trials Included in the Final Meta-Analysis (n = 50) [posted as supplied by author] Duration of Supplementa
Appendix 1 Characteristics of Trials Included in the Final Meta-Analysis (n = 50) [posted as supplied by author] Duration of Supplementa Participants tion, y (Average Age, y; (Follow-up Intervention vs.
More informationThe COSMOS Trial. (COcoa Supplement and Multivitamins Outcomes Study) JoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD, MPH
COSMOS Trial The COSMOS Trial (COcoa Supplement and Multivitamins Outcomes Study) JoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD, MPH Brigham and Women's Hospital Harvard Medical School Garnet L. Anderson,
More informationSeveral studies have reported that people with periodontal
Oral Health and Peripheral Arterial Disease Hsin-Chia Hung, DDS, DrPH; Walter Willett, MD, DrPH; Anwar Merchant, DMD, DrPH; Bernard A. Rosner, PhD; Alberto Ascherio, MD, DrPH; Kaumudi J. Joshipura, ScD
More informationA Proposed Randomized Trial of Cocoa Flavanols and Multivitamins in the Prevention of Cardiovascular Disease and Cancer
A Proposed Randomized Trial of Cocoa Flavanols and Multivitamins in the Prevention of Cardiovascular Disease and Cancer JoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD, MPH Brigham and Women's Hospital
More informationElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,
More informationUCLA Nutrition Bytes. Title. Permalink. Journal ISSN. Author. Publication Date. Vitamin C and Treating Coronary Artery Disease: More Hype than Hope?
UCLA Nutrition Bytes Title Vitamin C and Treating Coronary Artery Disease: More Hype than Hope? Permalink https://escholarship.org/uc/item/44m385rp Journal Nutrition Bytes, 14(1) ISSN 1548-601X Author
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION A Randomized Factorial Trial of Vitamins C and E and Beta Carotene in the Secondary Prevention of Cardiovascular Events in Women Results From the Women s Antioxidant Cardiovascular
More informationThe role of vitamin E in the prevention of coronary events and stroke
The role of vitamin E in the prevention of coronary events and stroke Meta-analysis of randomized controlled trials bdullah H. lkhenizan, CCFP, DCEpid, Mohammed. l-omran, MD, MSc (Epid). BSTRCT Cardiovascular
More informationConsiderable evidence supports the hypothesis
Relation of Consumption of Vitamin E, Vitamin C, and Carotenoids to Risk for Stroke among Men in the United States Alberto Ascherio, MD, DrPH; Eric B. Rimm, ScD; Miguel A. Hernán, MD, MPH; Edward Giovannucci,
More informationPapers. Abstract. Subjects and methods. Introduction
Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study Frank B Hu, Meir J Stampfer, JoAnn E Manson, Eric B Rimm, Graham A Colditz, Bernard A Rosner, Frank E Speizer,
More informationVarious studies have evaluated the antioxidant effects of vitamin E in the prevention or
REVIEW ARTICLE Vitamin E and Coronary Artery Disease Anne P. Spencer, PharmD; Deborah Stier Carson, PharmD; Michael A. Crouch, PharmD Various studies have evaluated the antioxidant effects of vitamin E
More informationLOW FOLATE INTAKE HAS INcreased
ORIGINAL CONTRIBUTION A Prospective Study of Folate Intake and the Risk of Breast Cancer Shumin Zhang, MD, ScD David J. Hunter, MBBS, ScD Susan E. Hankinson, ScD Edward L. Giovannucci, MD, ScD Bernard
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationSaturated fat- how long can you go/how low should you go?
Saturated fat- how long can you go/how low should you go? Peter Clifton Baker IDI Heart and Diabetes Institute Page 1: Baker IDI Page 2: Baker IDI Page 3: Baker IDI FIGURE 1. Predicted changes ({Delta})
More informationEuropean Journal of Cardiovascular Prevention & Rehabilitation
European Journal of Cardiovascular Prevention & Rehabilitation http://cpr.sagepub.com/ Antioxidant vitamins intake and the risk of coronary heart disease: meta-analysis of cohort studies Zheng Ye and Honglin
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationThe role of long-chain -3 fatty acids in the management
Clinical Investigation and Reports Fish and Long-Chain -3 Fatty Acid Intake and Risk of Coronary Heart Disease and Total Mortality in Diabetic Women Frank B. Hu, MD; Eunyoung Cho, ScD; Kathryn M. Rexrode,
More informationRational Use Of Vitamin Supplements in Clinical Practice: The Evidence For And Against
To Our Readers The current issue of the Updates Series on Nutrition in Disease Management features two articles. The first of these addresses an issue which is very relevant to every practitioner of Clinical
More informationSecrets of delaying aging and living disease free Part 1
Secrets of delaying aging and living disease free Part 1 Roman Pawlak, Ph.D, RD www.drromanpawlak.com Aging results in profound changes that effect all systems, organs and tissues. Pawlak R. Forever young.
More informationAspirin prevents stroke but not MI in women; Vitamin E has no effect on CV disease or cancer
MEDICAL GRAND ROUNDS CME CREDIT JULIE E. BURING, ScD* Professor of Medicine, Harvard Medical School; Division of Preventive Medicine, Brigham and Women s Hospital, Boston; principal investigator, Women
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1997, by the Massachusetts Medical Society VOLUME 336 J UNE 19, 1997 NUMBER 25 POSTMENOPAUSAL HORMONE THERAPY AND MORTALITY FRANCINE GRODSTEIN, SC.D., MEIR
More informationEPIDEMIOLOGY AND BIOSTATISTICS. Aspirin Use and Risk of Cataract in Posttrial Follow-up of Physicians Health Study I
EPIDEMIOLOGY AND BIOSTATISTICS Aspirin Use and Risk of Cataract in Posttrial Follow-up of Physicians Health Study I William G. Christen, ScD; Umed A. Ajani, MBBS; Debra A. Schaumberg, ScD; Robert J. Glynn,
More informationEgg Consumption and Risk of Type 2 Diabetes in Men and Women
Egg Consumption and Risk of Type 2 Diabetes in Men and The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version
More informationFish Intake, Marine Omega-3 Fatty Acids, and Mortality in a Cohort of Postmenopausal Women
American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 160, No. 10 Printed in U.S.A. DOI: 10.1093/aje/kwh307 Fish Intake, Marine
More informationDownloaded from journal.bums.ac.ir at 23:16 IRST on Saturday February 16th 2019
( ) - - - - :.. - : HDL-C.. ( )... P / t () : (P
More informationFolate and Vitamin B 6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women
Original Contributions Folate and Vitamin B 6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women Eric B. Rimm, ScD; Walter C. Willett, MD, DrPH; Frank B. Hu, MD, PhD; Laura
More informationPostintervention Effect of Alpha Tocopherol and Beta Carotene on Different Strokes
Postintervention Effect of Alpha Tocopherol and Beta Carotene on Different Strokes A 6-Year Follow-Up of the Alpha Tocopherol, Beta Carotene Cancer Prevention Study Markareetta E. Törnwall, MD, PhD; Jarmo
More informationUCLA Nutrition Noteworthy
UCLA Nutrition Noteworthy Title Vitamin C and the Risk of Coronary Heart Disease Permalink https://escholarship.org/uc/item/5xg9t04z Journal Nutrition Noteworthy, 4(1) ISSN 1556-1895 Author Chang, Angela
More informationHeart failure (HF) remains a major public health issue in
Egg Consumption and Risk of Heart Failure in the Physicians Health Study Luc Djoussé, MD, MPH, DSc; J. Michael Gaziano, MD, MPH Background Reduction in dietary cholesterol is widely recommended for the
More informationThe role of vitamin E (tocopherol) supplementation in the prevention
Review Article Schattauer 2011 579 The role of vitamin E (tocopherol) supplementation in the prevention of stroke A meta-analysis of 13 randomised controlled trials Qiong Bin; Xueying Hu; Yunfei Cao; Feng
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationModerate alcohol consumption is associated with decreased
Alcohol Consumption and Plasma Concentration of C-Reactive Protein Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Moderate alcohol intake has been associated with
More informationStroke is the third leading cause of death in the United
Original Contributions Prospective Study of Major Dietary Patterns and Stroke Risk in Women Teresa T. Fung, ScD; Meir J. Stampfer, MD, DPH; JoAnn E. Manson, MD, DPH; Kathryn M. Rexrode, MD; Walter C. Willett,
More informationFREE RADICALS CAN CAUSE LIPID
ORIGINAL CONTRIBUTION JAMA-EXPRESS in the Primary Prevention of Cardiovascular Disease and Cancer The Women s Health Study: A Randomized Controlled Trial I-Min Lee, MBBS, ScD Nancy R. Cook, ScD J. Michael
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationMultivitamin supplements are widely used in developed
Multivitamin Use and Risk of Stroke Mortality The Japan Collaborative Cohort Study Jia-Yi Dong, MMed; Hiroyasu Iso, MD, PhD; Akihiko Kitamura, MD, PhD; Akiko Tamakoshi, MD, PhD; Japan Collaborative Cohort
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationAssociation Between Consumption of Beer, Wine, and Liquor and Plasma Concentration of High-Sensitivity C-Reactive Protein in Women Aged 39 to 89 Years
Association Between Consumption of Beer, Wine, and Liquor and Plasma Concentration of High-Sensitivity C-Reactive Protein in Women Aged 39 to 89 Years Emily B. Levitan, MS a,e, Paul M. Ridker, MD, MPH
More informationIn a recent meta-analysis of randomized clinical trials, Miller
Brief Communication: The Prevalence of High Intake of Vitamin E from the Use of Supplements among U.S. Adults Earl S. Ford, MD, MPH; Umed A. Ajani, MBBS, MPH; and Ali H. Mokdad, PhD Article Background:
More informationName of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor
Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Policy #: 239 Latest Review Date: July 2010 Category: Laboratory Policy Grade: Active
More informationORIGINAL INVESTIGATION. An Update on Aspirin in the Primary Prevention of Cardiovascular Disease
ORIGINAL INVESTIGATION An Update on in the Primary Prevention of Cardiovascular Disease Rachel S. Eidelman, MD; Patricia R. Hebert, PhD; Steven M. Weisman, PhD; Charles H. Hennekens, MD, DrPH Background:
More informationn 3 FATTY ACIDS AND SUDDEN DEATH BLOOD LEVELS OF LONG-CHAIN n 3 FATTY ACIDS AND THE RISK OF SUDDEN DEATH
n 3 FATTY ACIDS AND SUDDEN DEATH BLOOD LEVELS OF LONG-CHAIN n 3 FATTY ACIDS AND THE RISK OF SUDDEN DEATH CHRISTINE M. ALBERT, M.D., M.P.H., HANNIA CAMPOS, PH.D., MEIR J. STAMPFER, M.D., DR.P.H., PAUL M.
More informationREVIEW ARTICLE. Blood Levels of Homocysteine and Increased Risks of Cardiovascular Disease
Blood Levels of Homocysteine and Increased Risks of Cardiovascular Disease Causal or Casual? REVIEW ARTICLE William G. Christen, ScD; Umed A. Ajani, MBBS; Robert J. Glynn, ScD; Charles H. Hennekens, MD
More informationTHE SAME EFFECT WAS NOT FOUND WITH SPIRITS 3-5 DRINKS OF SPIRITS PER DAY WAS ASSOCIATED WITH INCREASED MORTALITY
ALCOHOL NEGATIVE CORRELATION BETWEEN 1-2 DRINKS PER DAY AND THE INCIDENCE OF CARDIOVASCULAR DISEASE SOME HAVE SHOWN THAT EVEN 3-4 DRINKS PER DAY CAN BE BENEFICIAL - WHILE OTHERS HAVE FOUND IT TO BE HARMFUL
More informationORIGINAL INVESTIGATION. The Impact of Diabetes Mellitus on Mortality From All Causes and Coronary Heart Disease in Women
The Impact of Mellitus on Mortality From All Causes and Coronary Heart Disease in Women 20 Years of Follow-up ORIGINAL INVESTIGATION Frank B. Hu, MD; Meir J. Stampfer, MD; Caren G. Solomon, MD; Simin Liu,
More informationWhole-grain consumption and risk of coronary heart disease: results from the Nurses Health Study 1 3
Whole-grain consumption and risk of coronary heart disease: results from the Nurses Health Study 1 3 Simin Liu, Meir J Stampfer, Frank B Hu, Edward Giovannucci, Eric Rimm, JoAnn E Manson, Charles H Hennekens,
More informationPAPER Abdominal and total adiposity and risk of coronary heart disease in men
(2001) 25, 1047±1056 ß 2001 Nature Publishing Group All rights reserved 0307±0565/01 $15.00 www.nature.com/ijo PAPER Abdominal and total adiposity and risk of coronary heart disease in men KM Rexrode 1
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationDESPITE UNCERTAINTY REGARDing
ORIGINAL CONTRIBUTION JAMA-EXPRESS Vitamins E and C in the Prevention of Cardiovascular Disease in Men The Physicians Health Study II Randomized Controlled Trial Howard D. Sesso, ScD, MPH Julie E. Buring,
More informationCopyright, 1996, by the Massachusetts Medical Society
Copyright, 1996, by the Massachusetts Medical Society Volume 334 MAY 2, 1996 Number 18 LACK OF EFFECT OF LONG-TERM SUPPLEMENTATION WITH BETA CAROTENE ON THE INCIDENCE OF MALIGNANT NEOPLASMS AND CARDIOVASCULAR
More informationSection Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD
Prevention of dementia Author Daniel Press, MD Michael Alexander, MD Section Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD Deputy Editor Janet L Wilterdink, MD Last literature review version
More informationEffects of whole grain intake on weight changes, diabetes, and cardiovascular Disease
Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease Simin Liu, MD, ScD Professor of Epidemiology and Medicine Director, Center for Global Cardiometabolic Health Brown
More informationDietary Supplements and Health: Hype vs. Evidence
Dietary Supplements and Health: Hype vs. Evidence JoAnn E. Manson, MD, DrPH, FACE Chief, Division of Preventive Medicine Brigham and Women's Hospital Professor of Medicine and the Michael and Lee Bell
More informationConsumption of fruits and vegetables has been shown to
Intake of Flavonoids, Carotenoids, Vitamins C and E, and Risk of Stroke in Male Smokers Tero Hirvonen, MSc; Jarmo Virtamo, MD; Pasi Korhonen, MSc; Demetrius Albanes, MD; Pirjo Pietinen, DSc Background
More informationEffects of antioxidants on vascular health
Effects of antioxidants on vascular health Garry G Duthie and Mary C Bellizzi Rowett Research Institute, Aberdeen, UK Substantial in vitro and animal model evidence implicates the free radicalmediated
More informationPage down (pdf converstion error)
1 of 6 2/10/2005 7:57 PM Weekly August6, 1999 / 48(30);649-656 2 of 6 2/10/2005 7:57 PM Achievements in Public Health, 1900-1999: Decline in Deaths from Heart Disease and Stroke -- United States, 1900-1999
More informationCardiovascular diseases represent the number
... CONTINUING PHARMACY EDUCATION... Use of Alternative Pharmacotherapy in Management of Cardiovascular Diseases Larisa Chagan, PharmD; Anna Ioselovich, PharmD; Liya Asherova, PharmD; and Judy W. M. Cheng,
More informationA Prospective Study of Cigarette Smoking and Risk of Incident Hypertension in Women
Journal of the American College of Cardiology Vol. 50, No. 21, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.08.017
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationLESSONS FROM THE RESULTS OF OBSERVATIONAL STUDIES AND TRIALS OF BETA-CAROTENE AND VITAMIN E?
LESSONS FROM THE RESULTS OF OBSERVATIONAL STUDIES AND TRIALS OF BETA-CAROTENE AND VITAMIN E? Julie E. Buring, ScD American College if Epidemiology Chicago, September 2003 BETA-CAROTENE AND CANCER At the
More informationPHYSICAL INACTIVITY AND BODY
ORIGINAL CONTRIBUTION Relationship of Physical Activity vs Body Mass Index With Type 2 Diabetes in Women Amy R. Weinstein, MD, MPH Howard D. Sesso, ScD, MPH I. Min Lee, MBBS, ScD Nancy R. Cook, ScD JoAnn
More informationAntloxidant vitamins in the prevention of cardiovascular disease
European Heart Journal (1997) 18, 719-727 Clinical Perspective Antloxidant vitamins in the prevention of cardiovascular disease The epidemiological evidence Introduction Recent evidence suggests that in
More information( 1) Framingham Heart
( 1) ( 1) Framingham Heart Study [1] 1. (Am J Kidney Dis. 45: 223-232, 2005) 96 19 1 17 Framingham Heart Study ( 1) American Heart Association (1) (2) (3) (4) [2] (GFR) [3] ARIC [4] Cardiovascular Health
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationcoronary mortality in 5133 men and women aged y over I From the Epidemiology, Demography and Biometry Program, National
Vitamin E and vitamin C supplement use and risk of allcause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the,2 Katalin G Losonczy, Tamara
More informationInflammation plays a major role in atherosclerosis, 1 and
Soluble P-Selectin and the Risk of Future Cardiovascular Events Paul M. Ridker, MD; Julie E. Buring, ScD; Nader Rifai, PhD Background P-selectin, a cell-surface adhesion molecule involved in leukocyte
More informationPage: 1 of 11. Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Disease
Last Review Status/Date: June 2015 Page: 1 of 11 Diagnosis and Management of Description Homocysteine is an amino acid found in the blood; levels are inversely correlated with folate levels. Homocysteine
More informationGENETIC VARIATION IN THE EFFECT OF ALCOHOL CONSUMPTION ON MYOCARDIAL INFARCTION
GENETIC VARIATION IN ALCOHOL DEHYDROGENASE AND THE BENEFICIAL EFFECT OF MODERATE ALCOHOL CONSUMPTION ON MYOCARDIAL INFARCTION LISA M. HINES, S.M., MEIR J. STAMPFER, M.D., DR.P.H., JING MA, M.D., PH.D.,
More informationatherosclerosis Lipoproteins and the pathogenesis of CHOLESTEROL AND CARDIOVASCULAR DISEASE speculative; there is no universal agreement on how the
CHOLESTEROL AND CARDIOVASCULAR DISEASE Lipoproteins and the pathogenesis of atherosclerosis DANIEL STEINBERG, M.D., PH.D. ABSTRACT It is now clear that hypercholesterolemia can, in some instances, be a
More informationRisk Factors and Primary and Secondary Prevention of Coronary Heart Disease
Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College
More information